Bioequivalence Studies

If two medicines are bioequivalent there is no clinically significant difference in their bioavailability. Although bioequivalence is most commonly discussed in relation to generic medicines, it is important to note that bioequivalence studies are also performed for innovator medicines in some situations such as: between early and late clinical trial formulations or between the formulations used in clinical trials and the product to be marketed for new medicines when changes in formulation have occurred after an innovator product has been approved, for example a change in one or more excipients (inactive ingredients)

  • Pharmacokinetic Studies
  • Pharmacodynamic Studies
  • Clinical Studies
  • IVIVC
  • Earlier exposure on BE

Related Conference of Bioequivalence Studies

June 08-09, 2018

7th International conference on Pharmaceutical Auditing

Baltimore, Maryland, USA
June 27-28, 2018

4th International Conference on Drug Discovery, Designing and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-19, 2018

18th World Pharma Congress

Warsaw, Poland
September 18-19, 2018

6th European Biopharma Congress

Amsterdam, Netherlands

Bioequivalence Studies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in